Adverse cardiac events associated with antibody drug conjugates in cancer patients: a retrospective analysis on the FAERS database and randomized controlled trials., PMID:40455883
Management of Diffuse Large B-Cell Lymphoma as Post-Transplant Lymphoproliferative Disorder in a Kidney Transplant Recipient: A Case Report., PMID:40407632
B cell receptor silencing reveals origin and dependencies of high-grade B cell lymphomas with MYC and BCL2 rearrangements., PMID:40402557
Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's Macroglobulinemia., PMID:40382198
Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL., PMID:40377673
Combined Impact of Prior Polatuzumab Vedotin Plus Bendamustine and Rituximab Therapy and Myeloablative Conditioning on Early Post-Transplant BK Virus-Associated Hemorrhagic Cystitis., PMID:40336921
Glofitamab with Polatuzumab Vedotin in Refractory Burkitt's Lymphoma., PMID:40305722
Contemporary management of diffuse large B-cell lymphoma in Japan., PMID:40192055
Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC., PMID:40177869
Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States., PMID:40163049
An aggressive case of Fluid overload-associated large B-cell lymphoma (FO-LBCL) with CD20 down-regulation., PMID:40159287
Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After ≥ 2 Lines of Therapy: Matching-Adjusted Indirect Comparison., PMID:40153222
Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study., PMID:40134133
Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study., PMID:40085955
Gastrointestinal toxicity of antibody-drug conjugates: a pharmacovigilance study using the FAERS database., PMID:40033454
Polatuzumab vedotin and bendamustine (Pola-B) was effective for refractory CD20-negative double-expressor lymphoma., PMID:39976690
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma., PMID:39966020
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study., PMID:39908481
Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-cell lymphoma: a retrospective analysis., PMID:39907880
Polatuzumab vedotin extravasation injury: a case report., PMID:39862062
Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model., PMID:39832983
The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma., PMID:39798075
Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis., PMID:39793679
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients., PMID:39792424
The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma., PMID:39767565
Successful Treatment of Methotrexate-associated Lymphoproliferative Disorder with the Pola-R-CHP Regimen., PMID:39757000
Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know., PMID:39641680
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study., PMID:39641321
Primary Thyroid Lymphoma: A Rare Diagnosis Treated With Polatuzumab Vedotin., PMID:39548855
Real-world outcomes of diffuse large B-cell lymphoma treated with frontline R-CHOP(-like) regimens in an Asian multi-ethnic population., PMID:39542909
[Treatment of refractory diffuse large B-cell lymphoma involving the central nervous system with polatuzumab vedotin-based regimen: a case report and literature review]., PMID:39414613
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas., PMID:39404868
[Recent advances in the treatment of DLBCL]., PMID:39358300
Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease., PMID:39353813
Imaged Capillary Isoelectric Focusing Coupled to High-Resolution Mass Spectrometry (icIEF-MS) for Cysteine-Linked Antibody-Drug Conjugate (ADC) Heterogeneity Characterization Under Native Condition., PMID:39347563
The current landscape of frontline large B-cell lymphoma trials., PMID:39316716
Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system., PMID:39271716
Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma., PMID:39228298
[The Utility of Primary Prophylaxis with Pegfilgrastim in Combination with Polatuzumab Vedotin Therapy]., PMID:39191692
[Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development]., PMID:39191681
Using Cure Modelling for Cost Effectiveness in the NICE Technology Appraisal of Polatuzumab Vedotin in Combination for Untreated Diffuse Large B Cell Lymphoma: An External Assessment Group Perspective., PMID:39120843
Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol., PMID:39088571
A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)., PMID:38983914
Central nervous system relapse after combination therapy including polatuzumab vedotin in patients with diffuse large B-cell lymphoma., PMID:38939513
Unmet Needs in the First-Line Treatment of Diffuse Large B-cell Lymphoma: Expert Recommendations From the Asia-Pacific Region With a Focus on the Challenging Subtypes., PMID:38853026
Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?, PMID:38813707
Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database., PMID:38766629
Disseminated tuberculosis after Polatuzumab-Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma., PMID:38721565
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma., PMID:38700035
A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin., PMID:38695550
For research use only. Not for human or drug use.
